Stocktoria
LivaNova PLC LIVN
Nasdaq · XNAS · stock · Electromedical & Electrotherapeutic Apparatus · website · IPO 2015-10-19
LivaNova PLC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.4B | $1.3B | $1.2B | $1.0B | $1.0B |
| Gross profit | $939.9M | $853.5M | $755.8M | $707.2M | $706.0M |
| R&D expense | $185.8M | $182.5M | $193.8M | $155.8M | $183.4M |
| SG&A expense | $548.8M | $508.9M | $502.7M | $469.2M | $471.9M |
| Operating income | $199.4M | $129.1M | -$68.5M | -$76.8M | -$784,000 |
| Interest expense | — | — | $58.9M | $48.2M | $50.2M |
| Income tax | $21.6M | $25.1M | -$98.9M | $11.1M | $11.2M |
| Net income | -$242.5M | $63.2M | $17.5M | -$86.2M | -$135.8M |
| EPS (diluted) | $-4.45 | $1.16 | $0.32 | $-1.61 | $-2.68 |
| Operating cash flow | $254.3M | $183.0M | $74.9M | $69.9M | $102.5M |
| Free cash flow | $173.3M | $135.9M | $39.9M | $43.4M | $77.1M |
| Cash & equivalents | $635.6M | $428.9M | $266.5M | $214.2M | $208.0M |
| Inventory | $164.7M | $147.6M | $147.9M | $129.4M | $105.8M |
| Total assets | $2.6B | $2.5B | $2.4B | $2.3B | $2.2B |
| Total liabilities | $1.4B | $1.2B | $1.2B | $1.1B | $906.3M |
| Shareholders' equity | $1.2B | $1.3B | $1.3B | $1.2B | $1.3B |
Source: SEC EDGAR filings · CIK 0001639691 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.